Breaking News

Jubilant Biosys, Orion Enter Pain Management Discovery Pact

May 13, 2014

Aims to develop drug for unmet needs in pain management

Jubilant Biosys, a Bengaluru-based subsidiary of Jubilant Life Sciences, and Orion Corp., a large pharma company based in Finland, have entered a drug discovery collaboration to research small molecule inhibitors aimed at developing a drug for unmet needs in pain management.
 
Jubilant will provide drug discovery services across early discovery, synthetic and medicinal chemistry, including scale up and preclinical services. The research for the project will primarily take place at Jubilant Biosys R&D labs in India, as well as its Discovery Center in the U.S. Jubilant will receive research funding, pre-defined research milestones, as well as royalties on sales. Orion will retain ownership of the compounds developed under the collaboration with exclusive worldwide rights.
 
Dr. Subir Kumar Basak, president of Jubilant Biosys, said, “We are excited to partner with Orion to offer integrated drug discovery services. Over the past few years, we have been strengthening our therapeutic area focused discovery platform, and this partnership serves as a validation of our efforts. We are confident of offering successful results to Orion at various stages of research.”
 
Dr. Jukka Sallinen, head of CNS Research of Orion Pharma R&D, said, “Jubilant Biosys is widely recognized for its expertise in offering integrated services in Drug Discovery and Development Solutions and for its prodigious capabilities in Pain and Inflammation. With established ability to develop successful drugs, we consider Jubilant as our ideal partner to take forward our strategic business plans with optimum time-to-market and accuracy.”
 

Related Contract Manufacturing:

Related Compliance:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent